Pharmaceutical

Abstract

To provide a pharmaceutical filled with a tablet containing (A) a colorant and (B) a fragrance, and having resistance to discoloration.SOLUTION: A pharmaceutical comprises a tablet and a press-through pack sheet filled with the tablet, wherein the tablet contains (A) a colorant and (B) a fragrance, and the press-through pack sheet comprises a molded sheet containing polychlorotrifluoroethylene and an aluminum foil.SELECTED DRAWING: Figure 2

Description

[Technical field]

[0001] The present invention relates to a pharmaceutical product packaged in a press-through pack sheet (PTP sheet). [Background technology]

[0002] Tablets may contain colorants for the purposes of identification, masking color changes after storage, and improving the appearance. Also, flavorings may be added to reduce the unpleasant taste of the active pharmaceutical ingredient when taken. However, some of these ingredients have the problem of discoloring over time due to the effects of temperature and humidity. [Prior art documents] [Patent documents]

[0003] [Patent Document 1] JP 2004-250376 A Summary of the Invention [Problem to be solved by the invention]

[0004] The present invention has been made in consideration of the above circumstances, and has an object to provide a pharmaceutical product filled with a tablet containing (A) a dye and (B) a flavoring, which is inhibited from discoloring. [Means for solving the problem]

[0005] As a packaging form for tablets, there is a press-through pack (PTP) composed of convexly molded plastic and aluminum foil, etc. Tablets are filled into a pocket formed by molding plastic into a convex shape, and then sealed with aluminum foil, etc. By strongly pressing the plastic part, the aluminum foil, etc. is broken, and the tablet inside can be taken out. As a result of intensive research to achieve the above object, the present inventor found that the above problem can be solved by filling the above tablet into a press-through pack having a molded sheet containing polychlorotrifluoroethylene and aluminum foil, and thus came to make the present invention.

[0006] Accordingly, the present invention provides the following pharmaceutical agent: 1. A pharmaceutical product having a tablet and a press-through pack sheet filled with the tablet, The tablet contains (A) a colorant and (B) a flavoring agent, The press-through pack sheet comprises a molded sheet containing polychlorotrifluoroethylene and aluminum foil. 2. The pharmaceutical product according to 1, wherein the molded sheet containing polychlorotrifluoroethylene is a sheet laminated with polychlorotrifluoroethylene and polyvinyl chloride. 3. The pharmaceutical according to 1 or 2, wherein the component (A) is one or more selected from water-soluble dyes, vat dyes, oil-soluble dyes, pigments and their aluminum lakes, and colored herbal extract components. 4. The pharmaceutical according to any one of 1 to 3, wherein the component (B) is one or more selected from menthol, vanillin, citral, neral, geranial, nonenal, limonene, pinene, linalool, citronellol, geraniol, terpinene, myrcene, nootcan, naringin, γ-undecalactone, hexyl acetate, ethyl propionate, hexanol, and ethyl butyrate. Effect of the Invention

[0007] According to the present invention, it is possible to provide a pharmaceutical product filled with a tablet containing (A) a dye and (B) a flavoring, which is inhibited from discoloring. [Brief description of the drawings]

[0008] [Figure 1] FIG. 1 is a side view of a molded sheet according to an embodiment of the present invention. [Diagram 2] FIG. 2 is a side view of a press-through pack sheet filled with tablets. [Diagram 3] FIG. 2 is a view of the pocket forming (convex portion) side of a press-through pack sheet according to one embodiment of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] The present invention will be described in detail below. The pharmaceutical product of the present invention is a pharmaceutical product having a tablet and a press-through pack sheet filled with the tablet, the tablet containing (A) a colorant and (B) a flavoring, the tablet being filled in a pocket of a pocket-formed molded sheet, and sealed with aluminum foil or the like (hereinafter simply referred to as aluminum foil).

[0010] [tablet] The (A) colorant is used to improve the aesthetic appearance and distinguishability of the tablet, and is not particularly limited as long as it is used in pharmaceuticals, and may be used alone or in combination of two or more. Examples of the (A) colorant include water-soluble colorants, vat dyes, oil-soluble dyes, pigments, and aluminum lakes thereof, as well as colored herbal extracts. The (A) component of the present invention also includes colored herbal extracts other than white, which are blended as drugs (active ingredients).

[0011] Examples of water-soluble dyes include Red No. 2, No. 3, No. 102, No. 104 to No. 106, No. 213, No. 214, No. 227, No. 230 to No. 232, Yellow No. 4, No. 5, No. 202, No. 203, Blue No. 1, No. 202, No. 203, No. 205, Green No. 2, No. 3, No. 201, No. 204, No. 205, and the like.

[0012] Examples of vat dyes include Red No. 226, Blue No. 201, and No. 204. Examples of oil-soluble dyes include Red No. 218, No. 223, and No. 225, Yellow No. 201 and No. 204, Green No. 202, Orange No. 201, and No. 206. Examples of pigments include Red No. 202 to 208, No. 215, No. 219 to 221, and No. 228, Orange No. 203 to 205, and No. 207, Yellow No. 205, Brown No. 201, Purple No. 201, red ferric oxide, and yellow red ferric oxide. Furthermore, aluminum lakes of these dyes and the like can be mentioned. Examples of colored herbal extracts include berberine tannate, Scopolia extract, dried turmeric extract, and peony extract.

[0013] The amount of component (A) in the tablet is preferably 0.01 to 40% by mass, more preferably 0.05 to 25% by mass. The amount is preferably 0.01 to 200 mg, more preferably 0.05 to 100 mg per tablet. By making the amount equal to or greater than the lower limit, the aesthetic appearance and distinguishability of the tablet are further improved, and by making the amount equal to or less than the upper limit, discoloration of the tablet is further suppressed.

[0014] (B)Fragrance (B) The flavoring agent is used to improve the tablet's ingestibility by imparting a smell and taste to the tablet. It is not particularly limited as long as it is used in pharmaceuticals, and may be used alone or in combination of two or more. Examples of flavoring agents include menthol, vanillin, citral, neral, geranial, nonenal, limonene, pinene, linalool, citronellol, geraniol, terpinene, myrcene, nootcan, naringin, γ-undecalactone, hexyl acetate, ethyl propionate, hexanol, ethyl butyrate, etc. These flavoring agents may be included or combined to use a mixture of orange flavoring, apple flavoring, peach flavoring, grapefruit flavoring, lemon flavoring, etc.

[0015] The amount of component (B) in the tablet is preferably 0.001 to 5% by mass, and more preferably 0.005 to 1% by mass. It is preferably 0.01 to 15 mg, and more preferably 0.05 to 5 mg, per tablet. By making it equal to or more than the lower limit, the tablet's ingestibility is further improved, and by making it equal to or less than the upper limit, discoloration of the tablet is further suppressed.

[0016] The tablet of the present invention may contain other ingredients as shown below, as long as the effects of the present invention are not impaired. Examples of other ingredients include drugs, excipients, disintegrants, binders, sweeteners, flavoring agents, lubricants, coating agents, etc. These can be used alone or in combination of two or more in appropriate amounts.

[0017] [Drugs] Examples of drugs include nonsteroidal anti-inflammatory drugs such as ibuprofen, acetaminophen, acetylsalicylic acid, loxoprofen (loxoprofen sodium hydrate), naproxen, ketoprofen, indomethacin, bufexamac, diclofenac, alclofenac, etodolac, flurbiprofen, mefenamic, and piroxicam; central stimulants such as sodium benzoate, caffeine, and anhydrous caffeine; and nitrazepam. Hypnotics and sedatives such as pam, triazolam, phenobarbital, amibarbital, allylisopropylacetylurea, etc.; antiepileptics such as phenytoin, primidone, clonazepam, carbamazepine, valproic acid, etc.; anticonvulsants such as meclizine hydrochloride, etc.; psychoneurotic agents such as haloperidol, chlordiazepoxide, diazepam, sulpiride, etc.; antispasmodics such as atropine, etc.; cardiac stimulants such as digoxin, etc.; antiarrhythmics such as pindolol, disopyramide, etc.; hydrochlorothiazide, Diuretics such as spironolactone, triamterene, furosemide, bumetanide, etc.; antihypertensives such as prazosin hydrochloride, etc.; coronary vasodilators such as isosorbide dinitrate, nifedipine, dipyridamole, etc.; cough suppressants such as noscapine, tulopterol, tranilast, etc.; expectorants such as bromhexine hydrochloride, etc.; antibiotics such as erythromycin, josamycin, chloramphenicol, rifampicin, griseofulvin, etc.; antihistamines such as clemastine fumarate, etc.; dexamethasone, bevacizumab, etc. Examples of such agents include steroids such as tamethasone, prednisolone, danazol, and chlormadinone acetate; vitamins such as vitamin A and folic acid (vitamin M); agents for treating digestive diseases such as famotidine, metoclopramide, omeprazole, trepibutone, and sucralfate; clofibrate, mercaptopurine, methotrexate, aluminum hydroxide, dried aluminum hydroxide gel, synthetic hydrotalcite, magnesium oxide, and magnesium hydroxide.

[0018] When a drug is contained, the amount of the drug is preferably 0.1 to 90% by mass, and more preferably 1 to 60% by mass, in the tablet, and is preferably 0.1 to 300 mg, and more preferably 0.5 to 200 mg, in one tablet.

[0019] [Excipients] Examples of excipients include cellulose and cellulose derivatives such as crystalline cellulose; sugars such as lactose, lactose hydrate, mannitol, sorbitol, and erythritol; inorganic compounds such as anhydrous silicic acid, calcium hydrogen phosphate, potassium dihydrogen phosphate, sodium bicarbonate, sodium carbonate, corn starch, calcium carbonate, and titanium oxide, and triacetin.

[0020] When an excipient is contained, the amount of the excipient is preferably 5 to 80% by mass, and more preferably 8 to 50% by mass, in one tablet, and is preferably 5 to 270 mg, and more preferably 10 to 150 mg.

[0021] [Disintegrant] Examples of disintegrants include carmellose, carmellose calcium, carmellose sodium, croscarmellose sodium, carboxymethylcellulose calcium, crospovidone, low-substituted hydroxypropylcellulose, partially pregelatinized starch, and carboxymethylstarch sodium.

[0022] When a disintegrant is contained, the amount of the disintegrant is preferably 0.1 to 30% by mass, and more preferably 5 to 20% by mass, in one tablet, and more preferably 5 to 100 mg, and more preferably 10 to 60 mg.

[0023] [Binding agent] Examples of binders include cellulose derivatives such as hydroxypropyl cellulose, hydroxymethyl cellulose, hydroxypropyl methyl cellulose (hypromellose), methyl cellulose, and ethyl cellulose, polyvinylpyrrolidone, polyvinyl alcohol (partially saponified), polyethylene glycol, and gelatin.

[0024] When a binder is contained, the amount of the binder is preferably 1 to 20% by mass, and more preferably 2 to 10% by mass, in the tablet, and is preferably 1 to 60 mg, and more preferably 2 to 30 mg, in one tablet.

[0025] [Sweetener] Sweeteners include lactose, lactose hydrate, saccharin, sodium saccharin, sucralose, sucrose, glucose, acesulfame potassium, aspartame and the like.

[0026] When a sweetener is contained, the amount thereof is preferably 0.05 to 10% by mass in the tablet, and more preferably 0.05 to 30 mg per tablet.

[0027] [Flavoring agent] Examples of flavoring agents include ascorbic acid, citric acid, citric acid hydrate, sodium citrate, tartaric acid, lactic acid, and malic acid.

[0028] When a flavoring agent is contained, the amount thereof is preferably 0.05 to 10% by mass in the tablet, and more preferably 0.05 to 30 mg per tablet.

[0029] [lubricant] Lubricants include hydrated silicon dioxide, light anhydrous silicic acid, magnesium stearate, calcium stearate, polyethylene glycol, talc, stearic acid, sucrose fatty acid esters, sodium stearyl fumarate, macrogol 6000, and the like.

[0030] When a lubricant is contained, the amount thereof is preferably 0.1 to 5% by mass in the tablet, and more preferably 0.1 to 15 mg per tablet.

[0031] The tablets may be coated or uncoated. [Tablet coating agent] Examples of the coating agent include celluloses such as hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methyl cellulose, hydroxymethyl cellulose, and ethyl cellulose, gum arabic, carboxyvinyl polymer, polyvinylpyrrolidone, and polyvinyl alcohol.

[0032] When a coating agent is included, the amount thereof is preferably 0.5 to 5% by mass in the tablet, and more preferably 0.5 to 15 mg per tablet.

[0033] The tablet may be a single-layer tablet or a multi-layer tablet having two or more layers. In the case of a layered tablet, the components (A) and (B) may be in the same layer or in different layers.

[0034] [Tablet manufacturing method] The method for producing the tablet of the present invention is not particularly limited, and any known production method can be used. For example, there is a method having a step of mixing component (A), component (B), and other components as necessary, and a step of tableting the obtained mixture.

[0035] The components (A) and (B) may or may not be granulated. When granulated, the granulation method is not particularly limited, and dry granulation, fluidized bed granulation, melt granulation, and agitation granulation are preferred.

[0036] Methods for mixing the component (A), the component (B), and, if necessary, other components, include a container rotation method and an agitation method using rotation of an agitating blade.

[0037] The step of tableting the obtained mixture may be, for example, a method of tableting using a tablet press having a mortar and a pestle. As the tablet press, a rotary tablet press having high production efficiency is preferable. The rotary tablet press is equipped with a rotating plate. The rotation speed of the rotating plate can be appropriately adjusted. The rotation speed is preferably 10 to 100 rpm. The tableting pressure may be set so as to obtain the following tablet hardness.

[0038] The uncoated tablets (plain tablets) obtained above may be coated with a coating agent as necessary to form a coated tablet having a coating layer on the surface of the plain tablet. A common device can be used for coating. For example, a pan-type coating device such as HiCoater (manufactured by Freund Corporation) or AquaCoater (manufactured by Freund Corporation) can be used.

[0039] The shape of the tablet is preferably one having a flat (e.g., disc-shaped) body and bulging portions (spherical or frustum portions) bulging from the top and bottom surfaces, such as rounded R tablets or two-stage R tablets, Sumi square flat tablets, and Sumi round flat tablets. Note that "upper and lower surfaces" refer to the upper and lower surfaces when the tablet is placed flat. The dimensions of the tablet are not particularly limited, but from the viewpoint of ease of handling and swallowing, the diameter of the tablet body (tablet diameter) is preferably 6 to 13 mmφ, and the thickness of the tablet (including the bulge portion described below) is preferably 3 to 8 mm. The bulging portion may be asymmetrical from the top to the bottom, but is preferably symmetrical from the top to the bottom. From the viewpoint of tablet strength, the height of the bulging portion is preferably 0.5 to 2.0 mm. When the bulging portion is a spherical notch, the curve R (radius of curvature, which corresponds to R2 in the case of a two-stage R tablet) at the apex is preferably 7 mm or more. By setting the curve R at the apex of the spherical notch within the above range, adhesion to the punch surface during tableting can be suppressed. In addition, the curve R1 (radius of curvature) at the periphery of the spherical notch in a two-stage R tablet is preferably 1 mm or more from the viewpoint of ease of administration. In the present invention, from the viewpoint of ease of administration, it is preferable that each tablet shape falls within the following range. Standard R lock: R=4.0~24.0mm, land part=0.05~0.1mm - 2-stage R lock: R1 = 1.2~8.0mm, R2 = 4.5~21.5mm, land part = 0.05~0.1mm Sugar-coated R tablets: R=2.0~18.5mm, land part=0.01~0.1mm Round flat lock: R=0.7~5.0mm, land=0.05~0.1mm -Circular corner flat lock: Rise angle = 25~35°, Land part = 0.05~0.1mm Here, the meaning of each dimension is as follows: R: Radius of curvature of the spherical recess R1: Radius of curvature of the curve on the periphery of the spherical recess R2: Radius of curvature for the curve at the top of the spheric recess Land portion: The shortest distance from any point on the periphery of the land portion, which is an annular horizontal plane in plan view formed between the periphery of the spherical recessed portion or frustum portion and the outer periphery of the upper surface (or lower surface) of the tablet body, to the outer periphery of the upper surface (or lower surface) of the tablet body. Rising angle: The inclination angle of the side of the frustum with respect to the upper (or lower) surface of the tablet body

[0040] The hardness of the tablet may be set according to the tablet size, but is preferably 2 kgf or more, more preferably 3 kgf or more, and even more preferably 4 kgf or more, from the viewpoint of suppressing the decrease in hardness and expansion of the tablet over time. The upper limit of the tablet hardness is preferably 20 kgf or less from the viewpoint of disintegration.

[0041] [Press-through pack sheet] The present invention is a pharmaceutical product having the above-mentioned tablet and a press-through pack sheet filled with the tablet. This suppresses discoloration of the tablet. The press-through pack sheet 1 has a molded sheet 2 containing polychlorotrifluoroethylene and an aluminum foil 3. The molded sheet has a convex pocket 5 for filling the tablet 4, and the tablet can be airtightly packaged by filling the pocket 5 with the tablet 4 and sealing it with the aluminum foil 3. By pressing the molded sheet hard, the aluminum foil 3 is broken and the tablet inside is taken out. FIG. 1 is a side view of a molded sheet according to one embodiment of the present invention. FIG. 2 is a side view of a press-through pack sheet filled with a tablet. FIG. 3 is a view from the pocket (convex) side of the press-through pack sheet.

[0042] The molded sheet containing polychlorotrifluoroethylene may be a molded sheet made of polychlorotrifluoroethylene, a resin molded sheet made by mixing and kneading polychlorotrifluoroethylene with other resin materials described later, a laminated sheet made by bonding a sheet made of polychlorofluoroethylene with a sheet made of other resin, or a laminated sheet made by bonding a resin molded sheet made by mixing and kneading polychlorotrifluoroethylene with other resin materials described later and a sheet made of other resin. Among them, a laminated sheet made by bonding a sheet made of polychlorofluoroethylene with a sheet made of other resin is preferred. In the case of a laminated sheet, it is preferred that the other resin (polyvinyl chloride, etc.) is in contact with the tablet.

[0043] Other resin materials include polyvinyl chloride, polyvinylidene chloride, polypropylene, polyethylene, polyolefin, etc. Among these, polyvinyl chloride is preferred from the viewpoint of ease of molding.

[0044] The moisture permeability in the pocket is preferably 1.0 mg / 10 pockets·day or less, more preferably 0.5 mg / 10 pockets·day or less, even more preferably 0.4 mg / 10 pockets·day or less, and particularly preferably 0.3 mg / 10 pockets·day or less. The moisture permeability is measured according to JIS K 7129-2. By setting the moisture permeability to the above range, discoloration of the tablet is further suppressed.

[0045] The thickness of the molded sheet containing polychlorotrifluoroethylene is preferably 100 to 500 μm, more preferably 200 to 350 μm. By making it equal to or greater than the above lower limit, discoloration of the tablet is more suppressed. By making it equal to or less than the above upper limit, the tablet can be more easily removed from the sheet. In particular, in the case of a laminate sheet, the thickness of the sheet made of polychlorofluoroethylene is preferably 15 to 120 μm, more preferably 40 to 90 μm. By making it equal to or greater than the above lower limit, discoloration of the tablet is more suppressed. By making it equal to or less than the above upper limit, pockets can be easily formed.

[0046] The tablet storage section in which the tablets are filled is preferably a roughly cylindrical pocket molded with an open top. The diameter of the pocket molded (pocket diameter, 1 in FIG. 1) is preferably 0.1 to 7 mm larger than the diameter of the tablets to be filled, more preferably 0.5 to 5 mm, in order to suppress the travel distance of the tablets during transportation and to make the tablets less likely to break. Specifically, when the diameter of the tablets is 6 mm, it is preferably 6.1 to 13 mm, more preferably 6.5 to 11 mm. Similarly, the pocket depth (2 in FIG. 1) is preferably 0.1 to 5 mm larger than the thickness of the tablets, more preferably 0.5 to 2 mm. Specifically, when the thickness of the tablets is 4 mm, it is preferably 4.1 to 9 mm, more preferably 4.5 to 7 mm.

[0047] For sealing aluminum foil, use a coating that is appropriate for the plastic sheet to be attached. For example, a vinyl coat is used for non-oriented polypropylene (CPP). The amount of coating is 0.3 to 0.5 g / m 2 By setting the thickness within this range, the adhesion between the aluminum foil and the plastic sheet becomes good, and better sealing properties can be obtained.

[0048] The thickness of the aluminum foil is preferably 0.005 to 0.035 mm, more preferably 0.01 to 0.25 mm. By making the thickness equal to or more than the above lower limit, the aluminum foil is less likely to break during transportation, etc., and by making the thickness equal to or less than the above upper limit, the tablets are easily taken out.

[0049] [Drugs] The pharmaceuticals are not particularly limited as long as they are in the form of tablets, but include antipyretics and analgesics, general cold medicines, hypnotics and sedatives, anti-drowsiness drugs, sedatives, pediatric sedatives, digestive organ drugs, drugs containing histamine H2 receptor antagonists, antacids, stomachic drugs, intestinal regulators, digestive drugs, laxatives, gastrointestinal analgesics and antispasmodics, antidiarrheals, laxatives, anthelmintics, cardiac stimulants, arteriosclerosis drugs, vascular strengthening drugs, drugs for anemia, antitussives and expectorants, internal hemorrhoid drugs, vitamin-based preparations, calcium-based preparations, protein / amino acid-based preparations, women's medicines, contraceptives, antihistamine-based preparations, Chinese herbal medicine preparations, and herbal medicine preparations, all of which are suitable.

[0050] [Drug manufacturing method] The method for producing the pharmaceutical product is not particularly limited, and known methods can be used. For example, the tablet is filled in the pocket portion, and the tablet is heat-sealed with aluminum foil using a PTP packaging machine at a temperature of 140 to 160°C and a compression time of 0.1 to 3 seconds to obtain the pharmaceutical product. EXAMPLES

[0051] The present invention will be specifically described below with reference to examples and comparative examples, but the present invention is not limited to the following examples. In the following examples, unless otherwise specified, "%" in the composition indicates % by mass, and the amount of each component in the table is the amount converted into a pure content.

[0052] [Example] [Tablet manufacturing method] The ingredients were mixed in a plastic bag so that the total weight was 2 kg, and the composition shown in the table below was obtained. The mixed powder was compressed into tablets using a tablet press (LIBRA2: Kikusui Seisakusho Co., Ltd.) to a tablet hardness of approximately 5 kgf. [Packaging conditions] The tablets were filled into pockets of a molded sheet shown in the packaging material list in Table 1 below, covered with aluminum foil (aluminum foil (vinyl-coated), manufactured by Yamato Chemical Industry Co., Ltd.), and heat-sealed at a temperature of 140°C and a compression time of 2 seconds using a PTP packaging machine (K-200KS: Yamato Chemical Industry Co., Ltd.).

[0053] [Table 1] PVC: Polyvinyl chloride PCTFE: Polychlorotrifluoroethylene PE: Polyethylene PVDC: Polyvinylidene chloride

[0054] [evaluation] The packaged tablets were stored at 40°C and 75% RH for four months, and then the tablets were removed from the press-through pack sheet and the appearance of the tablet surface was observed to confirm whether or not there had been any discoloration from before the start of storage. ○: No change (no spotty color changes of 0.2 mm or more were observed) ×: Spotted discoloration of 0.2 mm or more (spotted discoloration of 0.2 mm or more is observed)

[0055] [Table 2]

[0056] [Table 3]

[0057] [Table 4]

[0058] [Table 5]

[0059] [Table 6]

[0060] The raw materials used in the above examples are shown below. Unless otherwise specified, the amounts of each component in the table are calculated as pure amounts. [Table 7]

[0061] [Table 8] [Explanation of symbols]

[0062] 1 Press-through pack sheet 2 Molded Sheet 3. Aluminum foil 4 tablets 5 Pocket molding

Claims

1. A pharmaceutical product comprising a tablet and a press-through pack sheet filled with the tablet, the tablet comprising (A) a colorant and (B) a flavoring, The press-through pack sheet comprises a molded sheet containing polychlorotrifluoroethylene and aluminum foil.

2. 2. The pharmaceutical product according to claim 1, wherein the molded sheet containing polychlorotrifluoroethylene is a sheet laminated with polychlorotrifluoroethylene and polyvinyl chloride.

3. 3. The pharmaceutical product according to claim 1 or 2, wherein the component (A) is at least one selected from the group consisting of water-soluble dyes, vat dyes, oil-soluble dyes, pigments, and aluminum lakes thereof, and colored herbal extracts.

4. The pharmaceutical product according to claim 1 or 2, wherein the component (B) is one or more selected from the group consisting of menthol, vanillin, citral, neral, geranial, nonenal, limonene, pinene, linalool, citronellol, geraniol, terpinene, myrcene, nootcan, naringin, γ-undecalactone, hexyl acetate, ethyl propionate, hexanol, and ethyl butyrate.

Images